Spermidine

Verdict: Suggestive Last reviewed: 2026-04-24 Triangulated against anchor: NMN (Suggestive)

TL;DR

Spermidine is a polyamine with strong preclinical autophagy-induction data and consistent observational signals tying dietary intake to longevity. Human RCT evidence is mixed: the largest cognitive-decline trial (SmartAge, n=100, 12 months) was null on its primary endpoint. Verdict: Suggestive — real biology, observational signal, but the best-powered human RCT to date did not confirm cognitive benefit.

What it is

A natural polyamine present in essentially all cells, abundant in foods like aged cheese, wheat germ, soybeans, mushrooms, and legumes. Endogenously synthesized; dietary intake supplements endogenous pools. Sold as supplement (wheat-germ-extract capsules typically delivering 1-6 mg/day; some "high-dose" products at 10+ mg). Madeo group is the dominant academic source.

Proposed mechanism

Induces autophagy via inhibition of EP300 (a histone acetyltransferase) and activation of TFEB-mediated lysosomal biogenesis. Autophagy is a well-established longevity-relevant pathway; spermidine is among the most potent natural autophagy inducers identified. Also has independent effects on mitochondrial function, cardiac aging (cardiac autophagy specifically), and immune function (T-cell function in aged animals).

Confidence: Established for autophagy-induction mechanism; Plausible for translation to human aging outcomes.

Evidence ladder

Invertebrate (T5)

Lifespan extension replicated in S. cerevisiae, C. elegans, and D. melanogaster. Effect sizes meaningful (10-30%) and mechanism (autophagy) consistent. Among the most reproducible polyamine findings in invertebrate aging.

Mouse / rat (T4)

• ITP status: not formally tested as a solo intervention in the standard ITP protocol (as of 2026-04). This is a meaningful gap.
• Eisenberg et al. 2016, Nat Med — spermidine extended median lifespan in mice and reduced cardiac aging markers; single-lab.
• Multiple replications in healthspan endpoints — cardiac function, cognitive performance, immune markers — across labs, generally consistent.
• 2024-2025 research showing spermidine supplementation and protein restriction protect from organismal and brain aging via independent mechanisms.
• Effect size: ~10-15% median lifespan extension where reported; healthspan effects more consistent.
• Replication: Healthspan replicated; lifespan extension less consistently reproduced at multi-lab scale.
• Sex / strain / dose: Heterogeneous data; doses translated from mouse to human via standard allometry land in the supplement-dose range.

NHP (T4)

No major NHP healthspan or lifespan data.

Human (T2 — and this is where the verdict is decided)

• Observational — multiple cohort studies (Bruneck cohort, JPHC) find higher dietary spermidine intake associated with reduced all-cause mortality. T2-like evidence but with classic dietary-cohort confounding (people who eat polyamine-rich foods differ in many ways).
• Pilot trial 2018 (Aging journal) — Madeo group, n=30, 3 months, subjective cognitive decline: tolerable, hint of cognitive benefit. Underpowered.
• SmartAge trial — randomized, double-blind, placebo-controlled, n=100, 12 months. Subjective cognitive decline population. Primary endpoint (mnemonic discrimination performance): null. This is the best-powered human RCT of spermidine to date and it did not show a significant effect. Important: secondary/exploratory endpoints showed some signals, but primary was null.
• Pekar 2025 — heterogeneous response: 42% improved, 30% no change, 28% worsened. Suggests responder vs non-responder populations or noise; without pre-specified responder analysis, hard to interpret.
• Cognitive observational meta-analyses — broadly positive for dietary spermidine and brain health markers.
• No mortality RCT, no hard-endpoint RCT, no large pre-registered confirmatory trial.

Confounds

• Dietary intake confounding — people with higher spermidine intake (Mediterranean-style diets) differ from those with lower intake on virtually every health-relevant variable.
• Bioavailability and tissue distribution — polyamines are heavily metabolized; oral spermidine's effect on tissue spermidine levels is less clear than the supplement marketing implies.
• Endogenous synthesis — bodies make spermidine; supplementation may be redundant in well-fed populations.
• The SmartAge null result is the dominant signal in the human evidence base and is often elided in popular discussions.

Conflict of interest scan

• Madeo group is the major academic origin; some commercialization ties (TLL Pharma / spermidineLIFE products) — apply 1-tier discount on commercially-tied trials.
• SmartAge was academically led; minimal direct industry conflict.
• Net: modest discount on the more enthusiastic narratives; SmartAge stands as cleanest evidence and was null.

Human translation

Honest read: spermidine is real biology, observational dietary data is consistently positive, and the best human RCT we have was null on its primary cognitive endpoint. The popular marketing far outruns this. Whether higher-dose, longer-duration, or different-population trials would show benefit is an empirical question — and one of the few where well-designed trials are actively in progress.

Calibrated verdict

Suggestive. Per methodology section 3, Suggestive is "T3 or T4 evidence with replication, but human data absent or null/early." Spermidine fits: T4 mouse data with healthspan replication (lifespan less so), human RCT evidence dominated by a null primary endpoint in the largest trial.

Compared to NMN (Suggestive), spermidine has comparably strong preclinical foundations and arguably better observational human data, but its largest RCT was null where NMN's small RCTs have been mixed-positive on surrogates. Both are correctly placed at Suggestive — the failures and gaps differ in shape, not magnitude.

Compared to rapamycin (Probable), spermidine lacks ITP testing and lacks a positive primary-endpoint human RCT. Both gaps are decisive.

Confidence interval on verdict

• Could move to Probable if (a) ITP tests spermidine and reports positive lifespan data in pooled analysis, OR (b) a well-powered cognitive or frailty RCT reports positive on a pre-specified primary endpoint.
• Could move to Mostly hype if subsequent RCTs replicate SmartAge's null result and the observational signal is shown to be confounded by Mediterranean-diet-style lifestyle factors.
• Most likely 2-year trajectory: stays at Suggestive; modest probability of upgrade if ongoing trials report positive.

Open questions

• Q: Has spermidine been formally proposed for ITP testing? Status?
• Q: What dose range and duration is needed in humans to meaningfully alter tissue (not just blood) spermidine, and was SmartAge under-dosed?
• Q: Do the responder-vs-non-responder patterns in Pekar 2025 reflect genuine population heterogeneity (e.g., baseline polyamine levels, autophagy capacity) or measurement noise?
• Q: How much of the observational dietary-spermidine-mortality association survives careful confounder adjustment?

Sources

• Eisenberg et al. 2016, Nat Med — Cardioprotection and lifespan extension by the natural polyamine spermidine
• Madeo group 2018, Aging — Pilot safety/tolerability trial in subjective cognitive decline
• SmartAge trial protocol, Cochrane CN-01943226
• SmartAge primary results, JAMA Network Open / PMC9136623
• 2025 review — Spermidine for cognitive ageing: insights from observational and interventional studies
• 2024 — Spermidine supplementation and protein restriction protect from organismal and brain aging independently
• 2026 review — Spermidine in the aging brain: mechanisms, preclinical evidence, clinical perspectives

Produced under methodology locked 2026-04-24. Triangulated against NMN anchor.